Skip to main content

Advertisement

Table 1 Univariate analysis of MBL, properdin, C3, C3d and C5b-9

From: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients

Plasma concentration At start hemodialysis At end hemodialysis P-valuea Controls P-valueb
MBL 879 (255–1572) 821 (319–1477) 0.005 784 (277–1449) 0.9
Properdin 16.8 (13.6–22.4) 18.0 (14.2–23.8) 0.01 13.0 (10.8–14.7) <0.0001
C3d 7.3 (5.6–10.1) 10.3 (7.4–16.9) <0.0001 2.7 (2.3–3.4) <0.0001
C5b-9 214 (166–419) 253 (187–487) <0.0001 141 (107–262) <0.0001
  1. Values are expressed as median (interquartile range). Increased levels of MBL, properdin, C3d and C5b-9 were found at the end of hemodialysis compared with at the start of hemodialysis and controls. MBL was significantly lower in hemodialysis patients suffering from a cardiovascular event. An association was found between MBL and the cumulative incidence of a cardiovascular event
  2. Italic values used to show which statistical testing was significant (below 0.05)
  3. CV-event cardiovascular event; MBL mannose-binding lectin
  4. a Wilcoxon signed-rank test, at start hemodialysis vs. at end hemodialysis. All P-values are two-sided
  5. b Mann–Whitney test, at end hemodialysis vs. controls. All P-values are two-sided
  6. c Mann–Whitney test. All P-values are two-sided
  7. d Log-rank test
  8. e Split by lowest 25 %
  9. f Split by 400 ng/mL
  10. g Split by highest 25 %
Plasma concentration No CV-event CV-event P-valuec   
MBL 1074 (428–1722) 464 (111–1102) 0.006   
Properdin 18.6 (14.0–24.0) 17.3 (15.1–23.4) 0.8   
C3d 10.3 (7.3–16.7) 10.8 (7.4–17.2) 0.8   
C3d/C3 8.2 (6.3–13.7) 8.6 (6.0–15.6) 0.5   
C3 1.28 (1.08–1.53) 1.32 (1.14–1.55) 0.6   
C5b-9 249 (182–513) 266 (194–473) 0.8   
  1. Values are expressed as median (interquartile range). Increased levels of MBL, properdin, C3d and C5b-9 were found at the end of hemodialysis compared with at the start of hemodialysis and controls. MBL was significantly lower in hemodialysis patients suffering from a cardiovascular event. An association was found between MBL and the cumulative incidence of a cardiovascular event
  2. Italic values used to show which statistical testing was significant (below 0.05)
  3. CV-event cardiovascular event; MBL mannose-binding lectin
  4. a Wilcoxon signed-rank test, at start hemodialysis vs. at end hemodialysis. All P-values are two-sided
  5. b Mann–Whitney test, at end hemodialysis vs. controls. All P-values are two-sided
  6. c Mann–Whitney test. All P-values are two-sided
  7. d Log-rank test
  8. e Split by lowest 25 %
  9. f Split by 400 ng/mL
  10. g Split by highest 25 %
% CV event-free survival Low level (%) High level (%) P-valued   
MBLe 42.30  74.10  0.003   
MBLf 48.50 74.30  0.02   
Properdine 65.40 74.10  0.6   
C3dg 67.50 66.70  0.8   
C3d/C3g 67.50  66.70  0.9   
C3g 68.80  63.00  0.7   
C5b-9g 67.50  69.20  0.4   
  1. Values are expressed as median (interquartile range). Increased levels of MBL, properdin, C3d and C5b-9 were found at the end of hemodialysis compared with at the start of hemodialysis and controls. MBL was significantly lower in hemodialysis patients suffering from a cardiovascular event. An association was found between MBL and the cumulative incidence of a cardiovascular event
  2. Italic values used to show which statistical testing was significant (below 0.05)
  3. CV-event cardiovascular event; MBL mannose-binding lectin
  4. a Wilcoxon signed-rank test, at start hemodialysis vs. at end hemodialysis. All P-values are two-sided
  5. b Mann–Whitney test, at end hemodialysis vs. controls. All P-values are two-sided
  6. c Mann–Whitney test. All P-values are two-sided
  7. d Log-rank test
  8. e Split by lowest 25 %
  9. f Split by 400 ng/mL
  10. g Split by highest 25 %